Lariciresinol

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

落叶松树脂醇是一种肠木脂素前体，它通过破坏真菌质膜而具有杀真菌活性，并且具有作为治疗人类真菌感染性疾病的新型抗真菌剂的治疗潜力。膳食落叶松树脂醇可以减弱人 MCF-7 乳腺癌异种移植物和致癌物诱发的大鼠乳腺肿瘤的乳腺肿瘤生长并降低血管密度。

Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.(In Vitro):In this study, the antifungal properties and mode of action of Lariciresinol were investigated. Lariciresinol displays potent antifungal properties against several human pathogenic fungal strains without hemolytic effects on human erythrocytes. To understand the antifungal mechanism of action of Lariciresinol, the membrane interactions of Lariciresinol were examined. Fluorescence analysis using the membrane probe 3,3'-diethylthio-dicarbocyanine iodide (DiSC(3)-5) and 1,6-diphenyl-1,3,5-hexatriene (DPH), as well as a flow cytometric analysis with propidium iodide (PI), a membrane-impermeable dye, indicated that Lariciresinol was associated with lipid bilayers and induced membrane permeabilization.

——

——

——

Angiogenesis

VEGFR

VEGFR

——

——

27003-73-2

360.406

C20H24O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (277.47 mM)

COc1cc(C[C@H]2CO[C@@H]([C@H]2CO)c2ccc(O)c(OC)c2)ccc1O

——

(-20℃)

With Ice Pack

≥ 2 years